Shanghai Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel ...
An international team of researchers has uncovered evidence of partial resistance to artemisinin derivatives -- the primary treatment for malaria -- in young children with severe malaria.
Spherix has been tracking the C3G market for over four years in both the U.S. and Europe. The studies have provided meaningful insights into physician perceptions of unmet needs and expectations for ...